For hormone receptor-negative HER2-low breast cancer after at least one line of chemotherapy, T-DXd or SG should be considered, while HER2-ultralow tumours should be treated with SG followed by other lines of chemotherapy [32,33]. This evidence concerns the gene ERBB2 and breast carcinoma.